Letters to the Editor

Oral anticoagulation and antithrombin III

We were interested to read the paper by Bull et al., attributing the increase in antithrombin III seen in patients on oral anticoagulant therapy to age and underlying disease rather than anticoagulant treatment itself. We have also measured antithrombin III in patients on oral anticoagulant therapy (nicoumalone) but compared results before and after stopping treatment. Two separate series of patients were studied. In both series antithrombin III was measured before stopping and eight days after complete discontinuation, in the first series of seven patients using the method of immunodiffusion with Behringwerke antibody and in the second series of 13 patients using chromogenic substrate assay with chromozym TH. In the second series seven of these 13 patients were followed up between 3 and 12 months later and repeat assay performed. Both series of patients showed a significant fall in antithrombin III after stopping treatment (see Table) and this change was still present at 3-12 months follow-up. These findings are in agreement with the findings of Refvem and colleagues who also followed antithrombin III activities after stopping anticoagulant treatment. In our study we also performed the ¹²⁵I fibrinogen scan during the eight-day period after stopping to ensure that changes were not due to rethrombosis during this period. None of the 20 patients studied showed positive scans.

We conclude that oral anticoagulants cause a true rise in antithrombin III activity. Measurements of antithrombin III were also carried out on days 1, 3 and 5 after stopping treatment. The mean fall in antithrombin III activity did not parallel the fall in prothrombin time nor activated partial thromboplastin time; but was maximal on day 8 after discontinuation. This suggests that this change is not an effect on synthesis as the turnover of antithrombin III is about 2-8 days, but on catabolism. We suggest that this increased destruction of antithrombin III is caused by increasing in vivo thrombin generation as the normal form of prothrombin is resynthesised when oral anticoagulants are discontinued.

ELIZABETH LOVE
DAVID TABERNER
ANN EASTON
National (UK) Reference Laboratory for Anticoagulant Reagents and Control, University Hospital of South Manchester, Withington Hospital, West Didsbury, Manchester M20 8LR

References


Accidental transplantation of tumour cells

In the February issue of your journal, Forbes et al. reported that “patients dying of malignant disease confined to the brain are the only cancer subjects who should be considered as sources of organs for transplantation.”

We disagree with this opinion, as, from our own experience we find that it is extremely difficult to be absolutely certain that the tumour is confined to the brain, even after a very thorough necropsy of the donor. Although, it is still a widely accepted fact that visceral metastasis of central nervous system (CNS) tumours are an exception. Nevertheless, our own research has clearly demonstrated that all primary CNS tumours, regardless of their histological type, can cause extraneural metastasis. In 1977, we studied 248 observations of extraneural metastasis found in the world literature, which for the most part occurred from glioblastomas and astrocytomas. These studies consisted mainly of subjects who had undergone several craniotomies, but spontaneous metastases, which are sometimes the first...
Oral anticoagulation and antithrombin III.

E Love, D Taberner and A Easton

*J Clin Pathol* 1981 34: 1065
doi: 10.1136/jcp.34.9.1065-a

Updated information and services can be found at:
http://jcp.bmj.com/content/34/9/1065.1.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/